Results 291 to 300 of about 411,072 (381)

Body surface mapping of counterclockwise and clockwise typical atrial flutter: a comparative analysis with endocardial activation sequence mapping

, 2000
A. SippensGroenewegen, Michael D. Lesh, Franz Xaver Roithinger, Willard S. Ellis, P. Steiner, Leslie A. Saxon, Randall J. Lee, Melvin M. Scheinman   +7 more
openalex   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, Volume 12, Issue 4, Page 2631-2642, August 2025.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source

Polymyositis-Induced Atrial Flutter: A Rare and Unexpected Arrhythmia in an Idiopathic Inflammatory Myopathy. [PDF]

J Investig Med High Impact Case Rep
Katwaroo A, Maharaj M, Ramcharan P, Seecheran V, Lalchansingh D, Seecheran R, Panday A, Seecheran N.   +7 more
europepmc   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, Volume 12, Issue 4, Page 3134-3144, August 2025.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source

Dysplasia of the tricuspid valve leading to recurrent atrial flutter and fibrillation: a case report. [PDF]

Eur Heart J Case Rep
Yoshida T, Gatterer E, Strouhal A, Harrer M, Stöllberger C.   +4 more
europepmc   +1 more source

Clinical characteristics and long‐term outcomes in patients with apical hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 4, Page 2887-2897, August 2025.
Abstract Aims As a special type of hypertrophic cardiomyopathy (HCM), apical HCM (ApHCM) has different clinical characteristics while its nature history and prognosis are not well recognized. We aimed to describe the characteristics and outcomes of ApHCM and identify predictors of adverse outcomes.
Meng Guo, Chuanfen Liu, Jingjing Ye, Jian Liu   +3 more
wiley   +1 more source

Unraveling the intricacies of typical atrial flutter. [PDF]

HeartRhythm Case Rep
Harvey M.
europepmc   +1 more source

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists

ESC Heart Failure, Volume 12, Issue 4, Page 2578-2582, August 2025.
Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP‐1 RAs remain inadequately characterized.
Haoran Jiang, Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Erika Nicolsen, Todd McVeigh, Oksana Kamneva, Marat Fudim   +6 more
wiley   +1 more source